Genenta Science SpA Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $25.00 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising long-term data from Genenta Science’s TEM-GBM study. The study revealed that Temferon, the company’s therapeutic candidate, has shown a significant survival benefit for patients with glioblastoma multiforme (GBM), a challenging condition to treat. Notably, patients in the long-term follow-up have demonstrated extended survival, with one patient showing no disease progression without needing additional therapies.
Furthermore, Genenta Science has initiated patient enrollment for a new Phase 1 study targeting genitourinary tumors, which marks an important expansion of Temferon’s application. This trial will assess the safety and efficacy of Temferon in patients with metastatic renal cell carcinoma, potentially offering new treatment avenues. These developments underscore Genenta’s strategic positioning to address unmet medical needs, contributing to Pantginis’s positive outlook and Buy rating.
According to TipRanks, Pantginis is an analyst with an average return of -19.6% and a 29.69% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Kura Oncology, and Krystal Biotech.